Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | UBE2N | P61088 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amotosalen SCHEMBL29442584 | 1.00 | MAOA (0.44) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| Amotosalen SCHEMBL4197287 | 0.99 | MAOA (0.43) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| Amotosalen SCHEMBL15229366 | 0.98 | MAOA (0.42) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| SCHEMBL3359066 | 0.93 | MAOA (0.42) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| SCHEMBL6993313 | 0.88 | MCL1 (0.41) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| SCHEMBL1115728 | 0.88 | L3MBTL1 (0.44) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL7001517 | 0.86 | MCL1 (0.41) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| SCHEMBL13078690 | 0.86 | MAOA (0.50) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| SCHEMBL21585417 | 0.85 | MAOA (0.42) | MAOAMAOBKDM4EALDH1A1MAPK1 | |
| SCHEMBL21585418 | 0.85 | MAOB (0.42) | MAOAMAOBKDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 545 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558463-B2 | Portable centrifuge device and method of use | ABC Med Tech Corp. (US) | 2026-02-24 | — | — | US | claimed |
| US-12514876-B2 | Cryoprecipitate compositions and methods of preparation thereof | CERUS CORPORATION (US) | 2026-01-06 | — | — | US | claimed |
| US-20250375477-A1 | SELECTIVE TOLERIZATION - METHODS OF SELECTIVELY GENERATING TOLEROGENIC DENDRITIC CELLS | TRANSIMMUNE AG (DE) | 2025-12-11 | — | — | US | claimed |
| US-20250345471-A1 | SYSTEMS AND METHODS FOR TREATING BIOLOGICAL FLUIDS | CERUS CORP (US) | 2025-11-13 | — | — | US | claimed |
| EP-4606379-A2 | KITS AND METHODS FOR PREPARING PATHOGEN-INACTIVATED PLATELET COMPOSITIONS | Cerus Corporation (US) | 2025-08-27 | — | — | EP | claimed |
| US-20250084370-A1 | METHODS FOR SELECTIVELY REDUCING IMMUNOGENICITY IN A TRANSPLANT | TRANSIMMUNE AG (DE) | 2025-03-13 | — | — | US | claimed |
| US-12214092-B2 | Systems and methods for treating biological fluids | CERUS CORPORATION (US) | 2025-02-04 | — | — | US | claimed |
| US-20240271094-A1 | COMPOSITIONS AND METHODS FOR PATHOGEN INACTIVATION OF PLATELETS | CERUS CORPORATION | 2024-08-15 | — | — | US | claimed |
| EP-4410318-A2 | CRYOPRECIPITATE COMPOSITIONS AND METHODS OF PREPARATION THEREOF | Cerus Corporation (US) | 2024-08-07 | — | — | EP | claimed |
| EP-4376860-A1 | METHODS FOR SELECTIVELY REDUCING IMMUNOGENICITY IN A TRANSPLANT | Transimmune AG (DE) | 2024-06-05 | — | — | EP | claimed |
| WO-1998030327-A1 | METHODS AND DEVICES FOR THE REDUCTION OF SMALL ORGANIC COMPOUNDS FROM BLOOD PRODUCTS | CERUS CORPORATION (US) | 1998-07-16 | — | — | WO | claimed |
| EP-0840781-A1 | METHODS AND DEVICES FOR THE REMOVAL OF PSORALENS FROM BLOOD PRODUCTS | Cerus Corporation (US) | 1998-05-13 | — | — | EP | claimed |
| WO-1997021346-A1 | INACTIVATION OF NON-ENVELOPED VIRUS | CERUS CORPORATION (US) | 1997-06-19 | — | — | WO | claimed |
| US-5593823-A | FOR A SUFFICIENT DURATION, INTENSITY AND WAVELENGTH | CERUS CORPORATION (US) | 1997-01-14 | — | — | US | claimed |
| WO-1996040857-A1 | METHODS AND DEVICES FOR THE REMOVAL OF PSORALENS FROM BLOOD PRODUCTS | CERUS CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996039820-A1 | METHODS OF INACTIVATING LEUKOCYTES AND INHIBITING CYTOKINE PRODUCTION IN BLOOD PRODUCTS | CERUS CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996014739-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | CERUS CORPORATION (US) | 1996-05-23 | — | — | WO | claimed |
| EP-0707476-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | STERITECH, INC (US) | 1996-04-24 | — | — | EP | claimed |
| US-5399719-A | 4'-/4-Amino-2-oxa/butyl-4,5',8-trimethylpsoralen; preparation of 4'-/omega-amino-2-oxa/alkyl-4,5',8-trimethylpsoralens by reacting analogous omega-hydroxy compound with methanesulfonyl chloride and base, with sodium azide, with reducing agent | STERITECH, INC. (US) | 1995-03-21 | — | — | US | claimed |
| WO-1995000141-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | STERITECH, INC. (US) | 1995-01-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558463-B2 | Portable centrifuge device and method of use | SELL, CEP170, CFD | MAOA 4721/4885MAOB 4791/4885KDM4E 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.